Related Experiment Video

Updated: May 18, 2026

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Bone marrow-derived mononuclear cell therapy for patients with ischemic heart disease and ischemic heart failure

Yanting Wen1, Bing Chen, Chen Wang

  • 1Medical School of Nanjing University, Center for Translational Medicine, Nanjing, China.

Expert Opinion on Biological Therapy
|September 8, 2012
PubMed

Insights

Bone marrow-derived mononuclear cells (BMMNCs) therapy significantly improves left ventricular ejection fraction (LVEF) in patients with ischemic heart conditions. This regenerative medicine approach shows greater efficacy in ischemic heart failure patients, supporting further clinical trials.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Cell Therapy

Background:

  • Ischemic heart disease (IHD) and ischemic heart failure (IHF) significantly impair cardiac function.
  • Current therapies for IHD/IHF offer limited improvement in cardiac remodeling and function.
  • Bone marrow-derived mononuclear cells (BMMNCs) represent a potential regenerative approach.

Purpose of the Study:

  • To evaluate the efficacy of BMMNCs therapy in improving cardiac function in patients with IHD or IHF.
  • To assess changes in left ventricular ejection fraction (LVEF) and volumes post-BMMNCs therapy.
  • To compare the effectiveness of BMMNCs therapy between IHD and IHF patient subgroups.

Main Methods:

  • A meta-analysis of relevant randomized controlled trials (RCTs) was conducted.
  • Data from 13 RCTs were analyzed using a random effects model.
  • Weighted mean difference was calculated for LVEF, left ventricular end-diastolic volume, and left ventricular end-systolic volume.

Main Results:

  • BMMNCs therapy significantly improved LVEF by 3.83% in patients with ischemic heart conditions compared to controls.
  • The therapy demonstrated a more pronounced LVEF improvement of 5.67% in patients with IHF.
  • A smaller but significant LVEF increase of 2.19% was observed in patients with IHD.

Conclusions:

  • BMMNCs therapy offers a moderate yet significant improvement in LVEF for patients with IHD and IHF.
  • The findings suggest BMMNCs therapy is a promising adjunct to standard care for heart failure.
  • Further RCTs with extended follow-up are warranted to confirm the safety and long-term efficacy of BMMNCs therapy.
Abstract

More Related Videos

Intramyocardial Cell Delivery: Observations in Murine Hearts08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...